Skip to main navigation Skip to search Skip to main content

Hepatic failure associated with imipramine therapy

  • Y. Ilan
  • , D. Samuel
  • , M. Reynes
  • , Ran Tur-Kaspa
  • Hadassah University Medical Centre
  • Albert Einstein College of Medicine
  • Hôpital Paul Brousse

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Imipramine is an antidepressant drug that is rarely associated with mild liver function abnormalities. These are usually minor and transient liver enzyme elevations which return to normal levels upon discontinuation of the drug. We describe a 48-year-old male who developed subfulminant hepatic failure after imipramine usage, with complete recovery within three months after discontinuation of the drug.

Original languageEnglish
Pages (from-to)79-80
Number of pages2
JournalPharmacopsychiatry
Volume29
Issue number2
DOIs
StatePublished - Mar 1996
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Hepatic failure associated with imipramine therapy'. Together they form a unique fingerprint.

Cite this